Oncolytics Biotech Inc T.ONC

Comparison

[lonc17]

Here are results from a P1/2 trial finished in 2019.  Similar results to ONC, and this led to the initiation of a 700+ patient P3 presently enrolling. 

In fact, ONC's results are much better (1CR and 8PR in 13 patients) vs. (1 CR and 10 PR in 32 patients).

There really can be no doubt that ONC is heading very quickly to a P3 in PDAC. 

Partnership/buyout on the way.

https://www.targetedonc.com/view/frontline-nalirifox-regimen-demonstrates-promising-activity-in-advanced-pdac

[Noteable]

The Nalirifox regimen is comprised of liposome injection (Onivyde) plus 5 fluorouracil/leucovorin plus oxaliplatin (Nalirifox), and is a further extension on the use of chemotherapy agents combined together for the treatment of pancreatic cancer  and which is heavy on the chemotherapy and associated chemotherapy side effects and light on innovation. Onivyde is currently approved in

[Lesalpes29]

f Interesting that results are good enough for a P3 in this very bad cancer. Let them talk at 10h this morning. BP already in the hunt for partnership or buyout? Why not! Have a good week